. Author manuscript; available in PMC: 2019 Feb 1.

Published in final edited form as: Breast Cancer Res Treat. 2017 Nov 7;167(3):731–740. doi: 10.1007/s10549-017-4533-9

Table 1.

Patient Demographic and Clinical Characteristics

Characteristic	Evaluable^* Patients (n=64)	PTEN IHC Available (n=59)	PIK3CA Mutation Available (n=46)	PTEN and PIK3CA Available (n=43)
Age, years
Median	50	50	50.5	50
Range	31–74	31–74	31–70	31–70

Tumor size, cm
Median	6	6	6	6
Range	1.5–30	2–30	1.5–30	2–30

Biomarkers^†
ER positive	31 (51%)	31(52%)	22 (49%)	22 (51%)
PR positive	22 (36%)	22 (37%)	17 (38%)	17 (40%)

Pathologic complete response
Yes	17 (27%)	14 (24%)	10 (22%)	8 (18%)
No	47 (73%)	45 (76%)	36 (78%)	35 (81%)

Abbreviations: ER, estrogen receptor; PR, progesterone receptor.

64 patients in the study were evaluable for efficacy

^†

ER, PR were from central review IHC, 61 out of 64 patients’ data were available